Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status

NCT01038037 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT01038037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01038037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status
Lead sponsor
Vejle Hospital
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2010
Completion date
December 31, 2013
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer